Healthcare

On Monday, September 28, 2026, MBX Biosciences (NASDAQ:MBX) rose 7.29% to finish at $57.54. The clinical-stage company develops precision peptide therapies for endocrine and metabolic disorders.

On Monday, September 28, 2026, DataMEDS AI (NASDAQ:MEDS), a penny stock, jumped 22.51% to finish at $3.81. The healthcare-technology company highlighted a mobile app launch and a deal involving Helomics, an AI-oriented cancer-laboratory business.

Lifecore Biomedical (NASDAQ:LFCR) was among the gainers in US markets on Monday, September 28, 2026, closing the session up 55.24% at $6.52. The company announced a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million.

Shares of Liquidia (NASDAQ:LQDA) ended Monday, September 28, 2026 higher by 7.66%, at $73.67. The biopharmaceutical company is best known for its work in pulmonary hypertension, a serious condition affecting the blood vessels of the lungs.

Kodiak Sciences (NASDAQ:KOD) more than doubled on Monday, September 28 after two experimental eye drugs hit their goals in a pivotal Phase 3 trial, turning a small biotech into the day's biggest story on a down day for Wall Street.

While chipmakers and software stocks sank on Monday, September 28, biotech delivered a string of eye-popping gains, led by Kodiak Sciences (NASDAQ:KOD), aTakeoverof Lifecore Biomedical (NASDAQ:LFCR) and a batch of deals and analyst calls.

● Lakewood-Amedex Biotherapeutics (LABT) closed at $1.15 on Monday, down 31.14% from $1.67, after a reported premarket gain.